Related Experiment Video

Updated: May 2, 2026

Rapid Screening of HIV Reverse Transcriptase and Integrase Inhibitors
05:46

Rapid Screening of HIV Reverse Transcriptase and Integrase Inhibitors

Published on: April 9, 2014

20.3K

Optimizing statin therapy in HIV-infected patients: a review of pharmacotherapy considerations

Ramin Ansari1, Hossein Khalili1, Keyhan Mohammadi2

  • 1Department of Clinical Pharmacy, Faculty of Pharmacy, Tehran University of Medical Sciences, Tehran, Iran.

BMC Cardiovascular Disorders
|May 31, 2025
PubMed

Insights

People living with HIV (PLWH) benefit from statin therapy for cardiovascular disease prevention. However, concerns about drug interactions with antiretroviral therapy (ART) create practice inconsistencies, necessitating further research for optimal statin use in PLWH.

Area of Science:

  • Cardiology
  • Infectious Diseases
  • Pharmacology

Background:

  • People living with HIV (PLWH) face increased risk of cerebrovascular and coronary artery disease.
  • Dyslipidemia is a key risk factor for major adverse cardiovascular events in PLWH.
  • Lipid profile alterations in PLWH stem from general risk factors, HIV infection, or antiretroviral drugs.

Purpose of the Study:

  • To review current literature on statin initiation for cardiovascular disease (CVD) prevention in PLWH.
  • To investigate and summarize clinically significant drug interactions between antiretroviral therapies (ARTs) and statins.

Main Methods:

  • Comprehensive literature search across Scopus, PubMed, Google Scholar, EMBASE, and Web of Science using PICO strategy.
  • Investigation of ART-statin drug interactions using the University of Liverpool's website.

Main Results:

  • Summarized findings from approximately 70 studies.
  • Developed a practical algorithm to guide statin therapy optimization in PLWH.
  • Identified guideline recommendations and current practices regarding statin use in PLWH.

Conclusions:

  • Further research is needed to define optimal statin initiation timing and dosing in PLWH.
  • A significant gap exists between clinical guidelines and practice due to concerns about ART-statin interactions.
Abstract

Keywords:
Antiretroviral therapyDrug interactionHuman immunodeficiency virusPharmacotherapyStatin

More Related Videos

An Affordable HIV-1 Drug Resistance Monitoring Method for Resource Limited Settings19:57

An Affordable HIV-1 Drug Resistance Monitoring Method for Resource Limited Settings

Published on: March 30, 2014

19.2K
Quantitative Structure-Activity Relationship, Activity Prediction, and Molecular Dynamics of Non-nucleotide Reverse Transcriptase Inhibitors10:29

Quantitative Structure-Activity Relationship, Activity Prediction, and Molecular Dynamics of Non-nucleotide Reverse Transcriptase Inhibitors

Published on: May 9, 2025

2.0K

Related Concept Videos

Lipid-Lowering Drugs: Statins and Miscellaneous Agents01:20

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
1.7K
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
741
Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment01:08

Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment

Hepatic impairment, characterized by decreased liver function, does not uniformly mandate adjustments in drug dosage. Whether dosage modifications are necessary depends on various factors related to the drug's metabolism and elimination pathways. If a drug is primarily excreted via the kidneys and bypasses significant hepatic processing, if it undergoes minimal metabolic transformation in the liver, or if it is volatile and primarily expelled through the lungs, dose adjustments may not be...
379
Retrovirus Life Cycles01:10

Retrovirus Life Cycles

Retroviruses have a single-stranded RNA genome that undergoes a special form of replication. Once the retrovirus has entered the host cell, an enzyme called reverse transcriptase synthesizes double-stranded DNA from the retroviral RNA genome. This DNA copy of the genome is then integrated into the host’s genome inside the nucleus via an enzyme called integrase. Consequently, the retroviral genome is transcribed into RNA whenever the host’s genome is transcribed, allowing the...
43.0K
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow01:26

Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow

Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug...
382
Therapeutic Drug Monitoring: Affecting Factors01:29

Therapeutic Drug Monitoring: Affecting Factors

Therapeutic Drug Monitoring (TDM) is the clinical practice of measuring specific drug levels in a patient's blood or body tissues to manage and optimize therapy. TDM is crucial for drugs with narrow therapeutic windows, like warfarin and phenytoin, where incorrect doses can lead to treatment failure or severe side effects. This monitoring ensures the dosage administered is within a safe and effective range. The factors affecting therapeutic drug monitoring include:Patient-Specific Factors:a.
429